Palisade Bio, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Wellington | fundamental | 2.90M | $5.08M | 0.00% | New | 2026-03-31 |
| RenTech | quant | 1.45M | $2.55M | 0.00% | Trimmed-39.0% | 2026-03-31 |
| StateStreet | passive | 636.2K | $1.11M | 0.00% | Trimmed-1.2% | 2026-03-31 |
| Citadel | multi-strat | 411.8K | $720.60K | 0.00% | Trimmed-96.1% | 2026-03-31 |
| TwoSigma | quant | 27.6K | $48.37K | 0.00% | Unchanged | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2025-11-10 | -0.27 | -0.38 | -39.03% |
| 2025-08-11 | -0.56 | -0.58 | -3.57% |
| 2025-05-12 | -0.81 | -0.47 | +41.98% |
| 2025-03-24 | -1.99 | -0.69 | +65.27% |
| 2024-11-12 | -3.35 | -2.32 | +30.85% |
| 2024-08-12 | -2.93 | -3.32 | -13.31% |
| 2024-05-13 | -3.75 | -4.59 | -22.40% |
| 2024-03-26 | -5.17 | -3.75 | +27.54% |
| 2023-11-09 | -6.15 | -7.35 | -19.51% |
| 2023-08-10 | -6.82 | -7.95 | -16.48% |
| 2023-05-11 | -9.90 | -8.10 | +18.18% |
| 2023-03-22 | -36.52 | -90.40 | -147.52% |
| 2022-11-14 | -67.50 | -61.06 | +9.53% |
| 2022-08-15 | -217.50 | -90.00 | +58.62% |
| 2022-05-13 | -217.50 | -179.74 | +17.36% |
| 2022-03-17 | -180.00 | -165.75 | +7.92% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| PALI | +6.53% | +25.44% | -9.79% | +186.49% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +3.56% | +30.08% | -6.34% | +173.80% |